PhRMA Japan Industry Vision Report

Japan’s rapidly aging population and recent changes to the policy environment have made reforms to the country’s health care system an urgent issue. This vision paper outlines the constructive role innovative biopharmaceutical companies can play to ensure new and innovative medicines continue to be developed and delivered to Japanese patients in a timely manner.

This patient-centric approach is supported by three key pillars: 1) Advancing innovation, 2) Securing patient access to new innovation in a sustainable universal healthcare system, and 3) Ensuring policy decisions are evidence based.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.